ReAlta Life Sciences, Inc.
Vision: Address life-threatening diseases through harnessing the power of the immune system.
Mission: ReAlta has developed a novel class of drugs with unique dual-targeting therapeutic capabilities that rebalance complement and inflammatory processes.
PIC 1 Platform
The ReAlta technology platform, termed “PIC1”, is a family of over 75 engineered peptides. This platform is uniquely multi-modal, with Complement inhibition (C1), anti-inflammatory, anti-oxidant and antimicrobial capabilities. Lab and animal research show this platform has the potential to provide game-changing therapy for over 25 unmet or under-addressed medical needs.